GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Cyclically Adjusted Price-to-FCF

Ainos (AIMD) Cyclically Adjusted Price-to-FCF : (As of May. 23, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Ainos Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ainos Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ainos's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Cyclically Adjusted Price-to-FCF Chart

Ainos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ainos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ainos's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Ainos's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ainos's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ainos's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ainos's Cyclically Adjusted Price-to-FCF falls into.



Ainos Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ainos's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ainos's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.26/131.7762*131.7762
=-0.260

Current CPI (Mar. 2024) = 131.7762.

Ainos Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.588 100.560 -2.081
201409 -1.510 100.428 -1.981
201412 0.000 99.070 0.000
201503 -0.294 99.621 -0.389
201506 -0.517 100.684 -0.677
201509 0.435 100.392 0.571
201512 -1.030 99.792 -1.360
201603 -0.026 100.470 -0.034
201606 -1.377 101.688 -1.784
201609 -0.477 101.861 -0.617
201612 -0.583 101.863 -0.754
201703 -0.444 102.862 -0.569
201706 -0.181 103.349 -0.231
201709 -0.141 104.136 -0.178
201712 -0.987 104.011 -1.250
201803 -0.178 105.290 -0.223
201806 -0.677 106.317 -0.839
201809 -0.670 106.507 -0.829
201812 -0.609 105.998 -0.757
201903 -0.416 107.251 -0.511
201906 -0.612 108.070 -0.746
201909 -0.449 108.329 -0.546
201912 -0.241 108.420 -0.293
202003 -0.220 108.902 -0.266
202006 -0.231 108.767 -0.280
202009 -0.302 109.815 -0.362
202012 -0.166 109.897 -0.199
202103 -0.378 111.754 -0.446
202106 0.102 114.631 0.117
202109 -0.277 115.734 -0.315
202112 -0.354 117.630 -0.397
202203 -0.793 121.301 -0.861
202206 -0.274 125.017 -0.289
202209 -0.339 125.227 -0.357
202212 -0.146 125.222 -0.154
202303 -0.376 127.348 -0.389
202306 -0.285 128.729 -0.292
202309 -0.192 129.860 -0.195
202312 -0.315 129.419 -0.321
202403 -0.260 131.776 -0.260

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ainos  (NAS:AIMD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ainos Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ainos's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ainos (AIMD) Business Description

Traded in Other Exchanges
N/A
Address
8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low dose oral form.
Executives
Meng Lin Sung officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc 10 percent owner 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei director 10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai director, officer: Chairman, CEO, CFO 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang director 5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang director NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin other: EVP - OPERATIONS 2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu director 9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai director 105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen director 1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen officer: VP, CFO 4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore director 402 FISH HATCHERY ROAD, HAMILTON MT 59840